Name: Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Best supportive care
Published: 2026-09-27T09:44:05-04:00

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Best supportive care

3 evidence topics · 3 sources

Composition of active symptom control in the ABC-06 trial

“ASC consisted of early identification and treatment of biliary-related complications and cancer-related symptom management; it could include (and was not limited to) the following as per requirements of individual patients: biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy (eg, for painful bone metastases), and transfusion of blood products.” (opens the source at this quote in a new tab)
“The overall survival rate in the ASC alone group was 35·5% (95% CI 25·2–46·0) at 6 months and 11·4% (5·6–19·5) at 12 months, compared with 50·6% (39·3–60·9) at 6 months and 25·9% (17·0–35·8) at 12 months in the ASC plus FOLFOX group.” (opens the source at this quote in a new tab)

Quality of life with active symptom control alone versus active symptom control plus FOLFOX

“FOLFOX did not worsen global, physical, social, or symptom QoL scores, whereas patients receiving ASC recorded declines across several domains.” (opens the source at this quote in a new tab)

Guideline recommendations for biliary drainage and infection

“In patients with biliary obstruction, biliary drainage and subsequent treatment should be carried out; when endoscopic access is not possible, percutaneous transhepatic drainage is recommended [IV, A]” (opens the source at this quote in a new tab)
“Sepsis secondary to biliary obstruction is common and should be treated promptly [IV, A]” (opens the source at this quote in a new tab)
“Patients should be advised of the likely duration of stent patency and of symptoms and signs which are indicative of biliary obstruction or infection [V, A]” (opens the source at this quote in a new tab)